A Study of the Systemic Absorption of MOB015B

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-12-16

Study Completion Date

2018-04-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A Study of the Systemic Absorption of Once Daily MOB015B when Applied for 28 Days in Subjects with Moderate to Severe Onychomycosis of the Toenails.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

An Open,Single-centre Pilot Study of Efficacy and Safety of Topical MOB015B in the Treatment of Distal Subungual Onychomycosis (DSO)

NCT01814020

Distal Subungual Onychomycosis

COMPLETED PHASE2

Efficacy and Safety of Two Treatment Regimens of Topical MOB015 in Adults With Distal Subungual Onychomycosis

NCT01246518

Onychomycosis

COMPLETED PHASE2

A Multi-centre, Double-blind, Randomized, Vehicle-controlled Study of Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO)

NCT02859519

Distal Subungual Onychomycosis

COMPLETED PHASE3

Study to Evaluate the Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO)

NCT02866032

Distal Subungual Onychomycosis

COMPLETED PHASE3

A Vehicle-controlled Study of Topical MOB015B in the Treatment of Distal Subungual Onychomycosis (DSO)

NCT05279846

Onychomycosis

ACTIVE_NOT_RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Onychomycosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

MOB015B

Group Type OTHER

MOB015B

Intervention Type DRUG

Topical formulation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MOB015B

Topical formulation

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subjects who understand the study procedures and agree to participate by providing written informed consent. Subject must be willing to authorize use and disclosure of protected health information collected for the study.
2. Male or female subjects 12 to 70 years of age (inclusive), at the time of consent.
3. Subject has a body mass index (BMI) from ≥ 18.5 to ≤ 35.0 (kg/m2), at the screening visit.
4. Females of childbearing potential must be using contraception during the study which can include abstinence or hormonal contraceptives. All women of childbearing potential must be willing to complete a urine pregnancy test on Days 1, 14, and 28.
5. Subjects must present with a clinical diagnosis of moderate to severe subungal onychomycosis with at least 50% involvement of both great toenails. In addition, 4 other toenails must be affected.
6. Subjects must have a positive KOH microscopy for at least 1 great toenail at the screening visit.
7. Subjects must be willing to complete clinical laboratory testing.
8. Subjects must be willing to undergo alcohol and drug (e.g., benzodiazepines, cocaine, opioids, cannabinoids, and barbiturates) tests at the Day 1 visit.
9. Subjects must be willing to remain at the study site for approximately 11 hours and undergo multiple blood draws on Day 1 and 28.
10. Subjects must be able to reach their toes to apply study drug or have a caregiver willing to help apply the study drug on a daily basis as directed.

Exclusion Criteria

1. Female subjects who are pregnant, nursing/breastfeeding, or plan to become pregnant within the study period.
2. Subjects with chronic or active liver disease, renal impairment, cutaneous or systematic lupus erythematosus, or any other disease or medical condition that in the opinion of the investigator would interfere with the study or place the subject at undue risk.
3. Subject with hypersensitivity to terbinafine or the vehicle excipients.
4. Subjects who have been treated with systematic formulations of terbinafine in the 12 months prior to the Day 1 visit.
5. Subjects who have been treated with topical formulations of terbinafine in the 6 months prior to the day 1 visit.
6. Subjects who take or have taken systematic medication that may interfere with the study or place the subject at undue risk in the 30 days before the day 1 visit (e.g., rifampin, cimetidine, phenobarbital, phenytoin, carbamazepine, terfenadine or digoxin).
7. Subjects who take or have taken systemic medication in the 30 days before the Day 1 visit that interferes with the terbinafine plasma assay.
8. Subjects who have consumed grapefruit products during the 30 days prior to the Day 1 visit.
9. Subjects who are not willing to refrain from caffeinated beverage consumption on Day 1 and 28.
10. Subjects with a current history of consumption of more than three alcoholic drinks per day or consumption of alcohol within 48 hours prior to Day 1 visit (one drink is equal to one unit of alcohol, one glass of wine, half pint of beer or one ounce of spirits).
11. Subjects with an ongoing or recent history of treatment for substance abuse.
12. Subjects who have participated in a study of an investigational drug 60 days prior to the Day 1 visit.
13. Subjects with a history of multiple syncopal episodes.
14. Subjects with positive tests for drugs or alcohol at Day 1 visit.
15. Subjects who are unable to comply with study requirements.
16. Subjects who are not willing to abstain from all toenail treatments such as toenail polish, pedicures and/or foot soaks (including nail clipping or debridement), for 3 days prior to Day 1 visit and during the study.
17. Donation of blood (one unit or 350 mL) within 90 days prior to Day 1 visit.

\-

Minimum Eligible Age

12 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No